A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection - Related Studies

A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection

This study has been completed.

Study NCT00001443. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Acquired Immunodeficiency Syndrome
		HIV Infections

2	Additional conditions recognized in this trial
		Communicable Diseases
		Immunologic Deficiency Syndromes
		Infection
		Syndrome

3	More general conditions related to this trial
		Disease
		Immune System Diseases
		Lentivirus Infections
		Pathologic Processes
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		indinavir (MK-0639)

5	Additional drug interventions recognized in this trial
		Indinavir

6	More general drug interventions related to this trial
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antiviral Agents
		Enzyme Inhibitors
		HIV Protease Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Protease Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		National Cancer Institute (NCI)